Please login to the form below

Not currently logged in
Email:
Password:

MNK-795

This page shows the latest MNK-795 news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offers $1.3bn for Cadence Pharma

company.". Mallinckrodt is also active in the analgesia sector and last year won priority review status from the FDA for MNK-795, a controlled-release oral formulation of oxycodone and acetaminophen

Latest news

  • FDA grants priority review to pain drug

    Mallinckrodt’s MNK-795 is intended for the management of moderate to severe acute pain. ... Mallinckrodt has won priority review from the US Food and Drug Administration (FDA) for its pain drug MNK-795.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics